Juan José Jaller-Raad

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

David Isenberg, Richard Furie, Nicholas S. Jones et al. · Arthritis & Rheumatology · 2021 · 134 citations

Medicine, Pharmacology, Pharmacotherapy +16

Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome

Felicia Cosman, Daria B. Crittenden, Serge Ferrari et al. · Journal of Bone and Mineral Research · 2018 · 78 citations · Full text

Medicine, Orthopaedic Surgery, Orthopedic Surgery +14

Chronic Joint Pain 3 Years after Chikungunya Virus Infection Largely Characterized by Relapsing-remitting Symptoms

Sarah R. Tritsch, Liliana Encinales, Nelly Pacheco et al. · The Journal of Rheumatology · 2019 · 73 citations · Full text

Medicine, Infectious Diseases, Internal Medicine +10

Incidence of Hip Fracture in Barranquilla, Colombia, and the Development of a Colombian FRAX Model

Juan José Jaller-Raad, J. J. Jaller-Char, J. A. Lechuga-Ortiz et al. · Calcified Tissue International · 2013 · 36 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +13

OP0233 EFFICACY, SAFETY, AND PHARMACODYNAMIC EFFECTS OF THE BRUTON'S TYROSINE KINASE INHIBITOR, FENEBRUTINIB (GDC-0853), IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS IN A PHASE 2 CONTROLLED STUDY

David Isenberg, Richard Furie, Nicholas S. Jones et al. · Annals of the Rheumatic Diseases · 2020 · 19 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17